At Insilico Medicine, human chemists still synthesize AI-proposed drugs, create variants, and test them on animals, and CEO Alex Zhavoronkov said those human contributors are the people who will be named on the patent.
Notes on verification
Directly quoted and corroborated by the original MIT Technology Review article and multiple independent secondary sources with consistent details. [tier=unverified indep_score=0.3 clusters=3 claim_tier=notable] [rescored 2026-09-15: curated origin-host map (PR #65); unclassified hosts no longer scored as aggregators]
Sources
- MIT Technology Review (seed:technology_and_ai)
- https://www.artiverse.ca/the-five-human-names-behind-an-ai-designed-drug/ (corroboration)
- https://bioethics.com/archives/103865 (corroboration)
- https://www.businessstory.org/2026/08/21/when-ai-designs-a-drug-who-gets-the-credit/ (corroboration)